Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Economic Development, Health, Industry, Intellectual Property, International Trade
|
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
|
Policies or Program
|
|
Aboriginal Affairs, Health
|
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
|
Policies or Program
|
|
Health, Industry
|
Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health, Industry, Intellectual Property
|
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
|
Policies or Program
|
|
Health, Industry
|
Communication to officials on labelling and product monographs.
|
Regulation
|
|
Health
|
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
|
Policies or Program
|
|
Health
|
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
|
Policies or Program
|
|
Economic Development, Health, Industry, Internal Trade, Research and Development, Science and Technology, Taxation and Finance
|
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health, Industry
|
Food and Drugs Act: Delays in product approvals and changes to existing products.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health, Industry, Intellectual Property
|
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Policies or Program, Legislative Proposal, Bill or Resolution, Regulation
|
|
Economic Development, Health, Industry, Intellectual Property
|
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
|
Regulation, Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Economic Development, Health, Industry, Internal Trade, Research and Development, Science and Technology
|
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
|
Policies or Program
|
|
Health, Industry
|
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
|
Regulation, Legislative Proposal, Bill or Resolution
|
|
Health
|
Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Economic Development, Health, Industry, International Trade, Taxation and Finance
|
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
|
Policies or Program
|
|
Environment, Health, Industry
|
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
|
Legislative Proposal, Bill or Resolution
|
Johnson & Johnson (Canada) Inc. is a subsidiary of US based Johnson & Johnson and is focused on the manufacture, development and sale of a broad range of products in the healthcare field, including medical devices and digital and robotic solutions and services. Johnson and Johnson (Canada) Inc. has no subsidiary companies, although another entity, Janssen Inc., which is also registered to lobby federally, may have a direct interest in its lobbying.
James Brodie, General Manager
Address:
200 Whitehall Drive
Markham, ON L3R 0T5
Canada
Telephone number:
905-946-2013
Johnson & Johnson (Canada) Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking